Condition: Ovarian Cancer · Sponsor: Nerviano Medical Sciences
This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
This description comes directly from the study's public registry record.
Domenico Roberti · +39 0331-581111 · clinicaltrials@nervianoms.com
Always discuss trial participation with your own doctor first.
| OSF Saint Francis Medical Center | Peoria, Illinois, United States | Recruiting |
| Washington University School of Medicine in St. Louis | St Louis, Missouri, United States | Recruiting |
| Penn Medicine - Perelman Center for Advanced Medicine | Philadelphia, Pennsylvania, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06930755